Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma

TK. Choueiri, P. Tomczak, SH. Park, B. Venugopal, S. Symeonides, J. Hajek, T. Ferguson, YH. Chang, JL. Lee, N. Haas, P. Sawrycki, N. Sarwar, M. Gross-Goupil, A. Thiery-Vuillemin, M. Mahave, G. Kimura, RF. Perini, TL. Saretsky, R. Bhattacharya, L....

. 2024 ; 29 (2) : 142-150. [pub] 20240202

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu randomizované kontrolované studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24007219

Grantová podpora
Merck Sharp & Dohme LLC

BACKGROUND: In patients with renal cell carcinoma (RCC) enrolled in the phase III KEYNOTE-564 trial (NCT03142334), disease-free survival (DFS) following nephrectomy was prolonged with use of adjuvant pembrolizumab therapy versus placebo. Patient-reported outcomes (PROs) provide an important measure of health-related quality of life (HRQoL) and can complement efficacy and safety results. PATIENTS AND METHODS: In KEYNOTE-564, 994 patients were randomly assigned to receive pembrolizumab 200 mg (n = 496) or placebo (n = 498) intravenously every 3 weeks for ≤17 cycles. Patients who received ≥1 dose of treatment and completed ≥1 HRQoL assessment were included in this analysis. HRQoL end points were assessed using the EORTC QLQ-C30, FKSI-DRS, and EQ VAS. Prespecified and exploratory PRO end points were mean change from baseline in EORTC QLQ-C30 GHS/QoL score, EORTC QLQ-C30 physical function subscale score, and FKSI-DRS score. RESULTS: No clinically meaningful difference in least squares mean scores for pembrolizumab versus placebo were observed at week 52 for EORTC QLQ-C30 GHS/QoL (-2.5; 95% CI -5.2 to 0.1), EORTC QLQ-C30 physical functioning (-0.87; 95% CI -2.7 to 1.0), and FKSI-DRS (-0.7; 95% CI -1.2 to -0.1). Most PRO scores remained stable or improved for the EORTC QLQ-C30 GHS/QoL (pembrolizumab, 54.3%; placebo, 67.5%), EORTC QLQ-C30 physical functioning (pembrolizumab, 64.7%; placebo, 68.8%), and FKSI-DRS (pembrolizumab, 58.2%; placebo, 66.3%). CONCLUSIONS: Adjuvant treatment with pembrolizumab did not result in deterioration of HRQoL. These findings together with the safety and efficacy findings support adjuvant pembrolizumab treatment following nephrectomy. TRIAL REGISTRATION: Clinicaltrials.gov Identifier: NCT03142334.

Chemotherapy Department Wojewódzki Szpital Zespolony im L Rydygiera Torun Poland

Department of Hematology and Oncology Sungkyunkwan University Samsung Medical Center Seoul South Korea

Department of Medical Oncology Edinburgh Cancer Centre NHS Lothian Institute of Genetics and Cancer University of Edinburgh Edinburgh UK

Department of Medical Oncology Fakultní Nemocnice Ostrava Ostrava Czech Republic

Department of Medical Oncology Fiona Stanley Hospital Perth Western Australia Australia

Department of Medical Oncology Lank Center for Genitourinary Oncology at Dana Farber Cancer Institute Brigham and Women's Hospital and Harvard Medical School Boston MA USA

Department of Medical Oncology Poznan University of Medical Sciences Poznan Poland

Department of Medical Oncology The Beatson West of Scotland Cancer Centre and University of Glasgow Glasgow UK

Department of Medical Oncology University Hospital Bordeaux Hôpital Saint André Bordeaux France

Department of Medical Oncology University Hospital Jean Minjoz Besançon France

Department of Oncology Asan Medical Center and University of Ulsan College of Medicine Seoul South Korea

Department of Oncology Fundación Arturo López Pérez FALP Santiago Chile

Department of Oncology Royal Free Hospital NHS Trust University College London London UK

Department of Surgery and Cancer Imperial College Healthcare NHS Trust London UK

Department of Urology Nippon Medical School Hospital Tokyo Japan

Department of Urology Taipei Veterans General Hospital Taipei Taiwan

Division of Hematology and Oncology Abramson Cancer Center Philadelphia PA USA

Merck and Co Inc Rahway NJ USA

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007219
003      
CZ-PrNML
005      
20240423155812.0
007      
ta
008      
240412s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/oncolo/oyad231 $2 doi
035    __
$a (PubMed)37589219
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Choueiri, Toni K $u Department of Medical Oncology, Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA $1 https://orcid.org/0000000292013217
245    10
$a Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma / $c TK. Choueiri, P. Tomczak, SH. Park, B. Venugopal, S. Symeonides, J. Hajek, T. Ferguson, YH. Chang, JL. Lee, N. Haas, P. Sawrycki, N. Sarwar, M. Gross-Goupil, A. Thiery-Vuillemin, M. Mahave, G. Kimura, RF. Perini, TL. Saretsky, R. Bhattacharya, L. Xu, T. Powles
520    9_
$a BACKGROUND: In patients with renal cell carcinoma (RCC) enrolled in the phase III KEYNOTE-564 trial (NCT03142334), disease-free survival (DFS) following nephrectomy was prolonged with use of adjuvant pembrolizumab therapy versus placebo. Patient-reported outcomes (PROs) provide an important measure of health-related quality of life (HRQoL) and can complement efficacy and safety results. PATIENTS AND METHODS: In KEYNOTE-564, 994 patients were randomly assigned to receive pembrolizumab 200 mg (n = 496) or placebo (n = 498) intravenously every 3 weeks for ≤17 cycles. Patients who received ≥1 dose of treatment and completed ≥1 HRQoL assessment were included in this analysis. HRQoL end points were assessed using the EORTC QLQ-C30, FKSI-DRS, and EQ VAS. Prespecified and exploratory PRO end points were mean change from baseline in EORTC QLQ-C30 GHS/QoL score, EORTC QLQ-C30 physical function subscale score, and FKSI-DRS score. RESULTS: No clinically meaningful difference in least squares mean scores for pembrolizumab versus placebo were observed at week 52 for EORTC QLQ-C30 GHS/QoL (-2.5; 95% CI -5.2 to 0.1), EORTC QLQ-C30 physical functioning (-0.87; 95% CI -2.7 to 1.0), and FKSI-DRS (-0.7; 95% CI -1.2 to -0.1). Most PRO scores remained stable or improved for the EORTC QLQ-C30 GHS/QoL (pembrolizumab, 54.3%; placebo, 67.5%), EORTC QLQ-C30 physical functioning (pembrolizumab, 64.7%; placebo, 68.8%), and FKSI-DRS (pembrolizumab, 58.2%; placebo, 66.3%). CONCLUSIONS: Adjuvant treatment with pembrolizumab did not result in deterioration of HRQoL. These findings together with the safety and efficacy findings support adjuvant pembrolizumab treatment following nephrectomy. TRIAL REGISTRATION: Clinicaltrials.gov Identifier: NCT03142334.
650    _2
$a lidé $7 D006801
650    _2
$a kvalita života $7 D011788
650    12
$a karcinom z renálních buněk $x farmakoterapie $x chirurgie $7 D002292
650    12
$a nádory ledvin $x farmakoterapie $x chirurgie $7 D007680
650    _2
$a hodnocení výsledků péče pacientem $7 D000071066
650    12
$a humanizované monoklonální protilátky $7 D061067
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a časopisecké články $7 D016428
700    1_
$a Tomczak, Piotr $u Department of Medical Oncology, Poznan University of Medical Sciences, Poznan, Poland
700    1_
$a Park, Se Hoon $u Department of Hematology and Oncology, Sungkyunkwan University Samsung Medical Center, Seoul, South Korea
700    1_
$a Venugopal, Balaji $u Department of Medical Oncology, The Beatson West of Scotland Cancer Centre and University of Glasgow, Glasgow, UK
700    1_
$a Symeonides, Stefan $u Department of Medical Oncology, Edinburgh Cancer Centre, NHS Lothian, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK
700    1_
$a Hajek, Jaroslav $u Department of Medical Oncology, Fakultní Nemocnice Ostrava, Ostrava, Czech Republic
700    1_
$a Ferguson, Thomas $u Department of Medical Oncology, Fiona Stanley Hospital, Perth, Western Australia, Australia
700    1_
$a Chang, Yen-Hwa $u Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan
700    1_
$a Lee, Jae Lyun $u Department of Oncology, Asan Medical Center and University of Ulsan College of Medicine, Seoul, South Korea
700    1_
$a Haas, Naomi $u Division of Hematology and Oncology, Abramson Cancer Center, Philadelphia, PA, USA
700    1_
$a Sawrycki, Piotr $u Chemotherapy Department, Wojewódzki Szpital Zespolony im. L. Rydygiera, Torun, Poland
700    1_
$a Sarwar, Naveed $u Department of Surgery and Cancer, Imperial College Healthcare NHS Trust, London, UK
700    1_
$a Gross-Goupil, Marine $u Department of Medical Oncology, University Hospital Bordeaux-Hôpital Saint-André, Bordeaux, France
700    1_
$a Thiery-Vuillemin, Antoine $u Department of Medical Oncology, University Hospital Jean Minjoz, Besançon, France
700    1_
$a Mahave, Mauricio $u Department of Oncology, Fundación Arturo López Pérez FALP, Santiago, Chile
700    1_
$a Kimura, Go $u Department of Urology, Nippon Medical School Hospital, Tokyo, Japan
700    1_
$a Perini, Rodolfo F $u Merck & Co., Inc., Rahway, NJ, USA
700    1_
$a Saretsky, Todd L $u Merck & Co., Inc., Rahway, NJ, USA
700    1_
$a Bhattacharya, Rituparna $u Merck & Co., Inc., Rahway, NJ, USA
700    1_
$a Xu, Lei $u Merck & Co., Inc., Rahway, NJ, USA
700    1_
$a Powles, Thomas $u Department of Oncology, Royal Free Hospital NHS Trust, University College London, London, UK
773    0_
$w MED00005061 $t The oncologist $x 1549-490X $g Roč. 29, č. 2 (2024), s. 142-150
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37589219 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155808 $b ABA008
999    __
$a ok $b bmc $g 2081295 $s 1216986
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 29 $c 2 $d 142-150 $e 20240202 $i 1549-490X $m The oncologist $n Oncologist $x MED00005061
GRA    __
$p Merck Sharp & Dohme LLC
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace